Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study

Michaël Hardy; Isabelle Michaux; Sarah Lessire; Jonathan Douxfils; Jean-Michel Dogné; Marion Bareille; Geoffrey Horlait; Pierre Bulpa; Céline Chapelle; Silvy Laporte; Sophie Testa; Hugues Jacqmin; Thomas Lecompte; Alain Dive; François Mullier

doi:10.1016/j.thromres.2020.10.025

Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study

Thromb Res. 2021 Jan:197:20-23. doi: 10.1016/j.thromres.2020.10.025. Epub 2020 Oct 24.

Authors

Affiliations

¹ Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium; Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
² Université catholique de Louvain, CHU UCL Namur, Department of Intensive Care, Yvoir, Belgium.
³ Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
⁴ Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium; Qualiblood s.a., Namur, Belgium.
⁵ Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.
⁶ Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
⁷ Unité de Recherche Clinique, Innovation, Pharmacologie, CHU Saint-Etienne, Hôpital Nord, F-42055 Saint-Etienne, France; SAINBIOSE U1059, Université Jean Monnet, University Lyon, INSERM, F-CRIN INNOVTE Network, F-42023 Saint-Etienne, France.
⁸ Haemostasis and Thrombosis Center, Cremona Hospital, Cremona, Italy.
⁹ Département de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva, Switzerland.
¹⁰ Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium. Electronic address: francois.mullier@uclouvain.be.

No abstract available

Keywords: COVID19; D-dimers; Factor VIII; Fibrinogen; Fibrinolysis; Intensive care; PAI-1; Thrombin generation.

Publication types

Letter
Observational Study

MeSH terms

Anticoagulants / therapeutic use
Biological Variation, Individual
Blood Coagulation Tests
C-Reactive Protein / analysis
COVID-19 / blood*
COVID-19 / complications
Female
Fibrin Fibrinogen Degradation Products / analysis
Fibrinolysis
Hemostasis*
Humans
Male
Plasminogen Activator Inhibitor 1 / blood
Prospective Studies
SARS-CoV-2*
Thrombin / analysis
Thrombophilia / blood
Thrombophilia / drug therapy
Thrombophilia / etiology*
Time Factors

Substances

Anticoagulants
Fibrin Fibrinogen Degradation Products
Plasminogen Activator Inhibitor 1
fibrin fragment D
C-Reactive Protein
Thrombin